Kami Guibi-tang治疗轻度认知障碍的有效性与安全性:一项试点随机安慰剂对照双盲试验的研究方案
本研究为单中心、随机、安慰剂对照、双盲试点试验,纳入遗忘型轻度认知障碍(aMCI)患者,随机分组接受Kami Guibi-tang(KGT)或安慰剂颗粒每日三次、共24周。主要结局为SNSB评分变化及MRI测量的脑代谢物、神经递质和脑血流变化,次要结局包括安全性和AD病理相关血液指标。该试验为首项探索KGT治疗aMCI潜力的临床研究。
要点
- KGT是韩医用于治疗健忘、失眠、食欲不振和抑郁的草药。
- 试验纳入aMCI患者,随机接受KGT或安慰剂治疗24周。
- 主要结局包括SNSB评分和MRI脑代谢物、神经递质及脑血流测量。
核心结论
- 该试点试验将首次评估KGT治疗遗忘型轻度认知障碍的有效性和安全性。
- 研究结果将为后续大规模试验提供可行性依据。
研究设计与样本
- 单中心、随机、安慰剂对照、双盲试点试验。
- 纳入诊断为遗忘型轻度认知障碍的合格参与者,随机分配至治疗组或对照组。
- 干预为KGT或安慰剂颗粒,每日三次,共24周。
- 主要结局为SNSB评分变化及MRI测量的脑代谢物、神经递质和脑血流变化。
- 次要结局包括血液化学变化、AD病理相关血液蛋白和胆固醇水平变化,以及以年龄和基因型为协变量的两组MRI变化比较。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Mild cognitive impairment (MCI) is an intermediate phase between normal aging and dementia. Since a majority of amnestic MCI (aMCI) cases progress to Alzheimer's disease (AD), it is considered the prodromal stage of AD and, therefore, a treatment target for the prevention of further cognitive decline. However, there is no approved treatment for MCI at present. Kami Guibi-tang (KGT) is a herbal drug used in Korean medicine to treat amnesia, insomnia, loss of appetite, and depression. We will explore the effectiveness and safety of KGT in amnestic MCI in this trial. METHODS/DESIGN: The study will be a single-center, randomized, placebo-controlled, double-blind trial. Eligible participants diagnosed with amnestic MCI will be randomly allocated to a treatment or control group. Participants will take KGT or placebo granules, three times a day, for 24 weeks. The primary outcomes will be changes in Seoul Neuropsychological Screening Battery (SNSB) scores, and magnetic resonance imaging (MRI) measurements including those of brain metabolites, neurotransmitters, and cerebral blood flow. The secondary outcomes will include the safety assessment, measured by changes in blood chemistry, changes in blood protein and cholesterol levels related to AD pathology, and a comparison of MRI changes between the two groups, using age and genotype as covariates. DISCUSSION: This study will be the first clinical trial to identify the therapeutic potential of Kami Guibi-tang for amnestic MCI. The findings will provide insight into the feasibility of large-scale trials to gather evidence for KGT as a treatment for MCI. TRIAL REGISTRATION: Korean Clinical Trial Registry, ID: KCT0002407 . Registered on 30 March 2017.
引用
- Shin HY, Kim JH, Jahng GH, et al. The effectiveness and safety of Kami Guibi-tang for mild cognitive impairment: study protocol of a pilot, randomized, placebo-controlled, double-blind trial. Trials. 2019. PMID: 31331367. doi:10.1186/s13063-019-3567-1
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。